OncoSec Medical Inc (ONCSQ)

[cameron12x]

I don't believe we were discussing patents.

Here, let us educate you about Dr. Pierce's background:

http://investing.businessweek.com/research/stocks/people/person.asp?personId=252870140&ticker=ONCS

Dr. Robert Hamilton Pierce M.D. has been the Chief Scientific Officer and Global Head of R&D at OncoSec Medical Incorporated since September 16, 2014. Dr. Pierce served as the Chief Medical Officer of OncoSec Medical Incorporated since December 12, 2013 until September 16, 2014. Dr. Pierce served at Merck Research Labs -- Palo Alto where he spent almost seven years in leading a 20--person team, dedicated to developing disease-oriented and tissue-based translational medicine platforms. From 2001 to 2007, he served several leadership positions at the University of Rochester School of Medicine, including Director of the Autopsy Service at Strong Memorial Hospital. Dr. Pierce was responsible for contributions to multiple successful IND applications, including critical biomarker development programs such as the anti-PD-L1 immunohistochemistry assay supporting Merck's MK-3475 trials. He was instrumental in designing two Phase 2 anti-PD-1 (MK-3475) oncology studies. He focused on immunomodulatory receptor (IMR) programs. He served as a Discovery Project Team Leader for two novel drug candidates. He served as an Executive Director of Merck Research Labs. He practiced as a staff pathologist to develop the graduate curriculum in pathomechamism of disease. He was the principal investigator of a RO1-funded research lab, Dr. Pierce played an important role in the university's clinical and academic research programs. He is the co-author of over fifty peer-reviewed journal articles and book chapters, and is a reviewer for numerous scientific journals as well as National Institute of Health grants. Dr. Pierce is well regarded for his career-long research into mechanisms of immune tolerance and has drug development experience. He is a key Member of the global development team behind Merck's FDA-designated "breakthrough" anti-PD-1 program (MK-3475). He was a Fulbright Award recipient. He studied Philosophy at the Albert-Ludwigs-University in Freiburg, Germany. He is a graduate of Yale College and Brown University School of Medicine. Dr. Pierce received his Post-Doctoral Training at the University of Washington, Seattle, WA. He trained at Brown University School of Medicine in Providence, RI, and received an Undergraduate Education at Yale University in New Haven, CT.